Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
about
5-HT(1A) receptor function in major depressive disorderAn overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levelsCognitive enhancement in schizophrenia: pharmacological and cognitive remediation approachesd-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.Randomized Controlled Trials of Add-On Antidepressants in SchizophreniaAdjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacySerotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine.Tandospirone, a 5-HT1A partial agonist, ameliorates aberrant lactate production in the prefrontal cortex of rats exposed to blockade of N-methy-D-aspartate receptors; Toward the therapeutics of cognitive impairment of schizophrenia.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression.Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data.A triple-blinded, randomized, placebo-controlled trial to examine the efficacy of buspirone added to typical antipsychotic drugs in patients with chronic schizophrenia.Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal FunctionNeural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophreniaA neurochemical yin and yang: does serotonin activate and norepinephrine deactivate the prefrontal cortex?Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.The treatment of cognitive impairment in schizophrenia.Trazodone: properties and utility in multiple disorders.Can genetics inform the management of cognitive deficits in schizophrenia?Pharmacotherapy of cognitive deficits in schizophrenia.Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.Emerging drugs for schizophrenia: an update.Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis.Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole.Quetiapine and Buspirone Both Elevate Cortical Levels of Noradrenaline and Dopamine In vivo, but Do Not have Synergistic Effects.Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders.Serotonin 1A receptors in the action of antipsychotic drugs: comment on 'Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone' by Frankle et al. 2011; 25(The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats.Possible dose-side effect relationship of antipsychotic drugs: relevance to cognitive function in schizophrenia.Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
P2860
Q24643511-3EAC8986-E7AA-4220-BF7C-9B186F48BADEQ26751302-798F2E1C-BD04-4A3A-93B6-529D2ACC442FQ26864324-936CD1A6-2598-4BF1-9AE7-E4C085AF7E60Q28067851-A6410C9D-7028-429A-BAD6-EF7521095FF1Q28080437-B4F837FB-8009-489A-B926-2C29FA2669DAQ28297813-6D3D8AC0-278F-494A-934E-EAEFFCA5CC80Q30445192-A82078AB-B935-43BF-A5CB-07D0B3418038Q34127055-E21C1448-59B1-43E2-88E2-428955CCB3D1Q34274859-F0E27441-792C-4299-9600-CC0AA48DD5E8Q34335586-4E0C6C71-2306-40C3-9CBF-B21B82D43025Q34350194-D58C1EBA-CBB3-4C93-97CF-37F2596AC708Q34640741-B1E084B4-545B-4A71-B8A7-1C7DEA50384BQ34646717-D90C6A0F-A444-4D68-B2B9-510F952FB0BFQ34653803-77C63217-878E-4E56-8288-97660B01C58FQ35450483-451F7296-E2CB-4D22-A67A-FE250AC16288Q35454624-C690AA53-6DC2-465D-A02E-5E4C2653273CQ36020776-C9D014A9-AB8A-493D-9C54-B49788B0B998Q36594948-13652A87-2E58-4522-824F-5A7020FF70A1Q37231628-848B01CC-76AB-404E-B2EE-27EFF14B12D8Q37729903-F6D798A8-6F83-4332-9D06-49983E6B76B8Q37811038-BD54EA3D-CD8B-41C2-93B1-D789C4C0F399Q37813206-6BCAA769-4805-4FE4-810D-8A6843AA02A9Q37960634-347DA00A-354B-49E1-B28F-EBEDDC5562D9Q37983548-C740323E-24D5-4BBD-8E71-11C376B38041Q38162531-982C82B5-7DF2-439E-AB91-A02E1959BAEEQ38187948-7BEF837B-5364-4E23-9F7D-C79C98722C77Q38252404-F6119AEB-FDA5-4B3E-A96C-6F446B845E5DQ38258215-10C66125-02F4-42CD-BFB8-8ABCC33BC471Q38268878-926ED49D-07A0-4AE9-9442-93413AF4B1D5Q41828115-4DB235D7-7294-4736-A932-630DCCB5D8C1Q42325246-ACDFE515-7FAC-44BE-ADBA-396E49F306E3Q47920400-7BEBF207-7F0E-46CF-A9A5-46BC7296F0AEQ48421481-584A03AD-550A-4023-980E-8F843079E06CQ50974329-AF439ACF-5AFE-4BA7-8793-414C7B825390Q51947237-4E42C4C5-3096-4267-8AC1-937FF8BE35E4Q58561523-B8758BB2-7371-4A8D-A4B3-770F5A6D3C77
P2860
Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@ast
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@en
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@nl
type
label
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@ast
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@en
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@nl
prefLabel
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@ast
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@en
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@nl
P2093
P1476
Effect of buspirone, a seroton ...... ind, placebo-controlled study.
@en
P2093
Ajanta Roy
Aygun Ertugrul
Herbert Y Meltzer
Sohee Park
Tomiki Sumiyoshi
P304
P356
10.1016/J.SCHRES.2007.06.008
P407
P577
2007-07-12T00:00:00Z